Steroids for multiple sclerosis and optic neuritis: A meta-analysis of randomized controlled clinical trials

Journal of Neurology

Volumn 247, Issue 6, 2000, Pages 435-442

  Brusaferri, Fabio ^a   Candelise, Livia ^b  

^a MAGGIORE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Adrenocorticotropic hormone; Meta analysis; Multiple sclerosis; Optic neuritis; Steroids

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; METHYLPREDNISOLONE; PREDNISONE; STEROID;

ACNE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIPLE SCLEROSIS; OPTIC NERVE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; SLEEP DISORDER; TASTE DISORDER; TIME; TREATMENT OUTCOME; VISUAL ACUITY; WEIGHT GAIN;

DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; MULTIPLE SCLEROSIS; OPTIC NEURITIS; RANDOMIZED CONTROLLED TRIALS; RECOVERY OF FUNCTION; STEROIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033946875     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150070172     Document Type: Article

References (36)

1. 1. Andersson PB, Goodkin DE (1998) Glucocorticosteroids therapy for multiple sclerosis: a critical review. J Neurol Sci 160:16-25
2. 2. Beck RW, Cleary PA, Anderson MM, Keltner JL, Shults WT, Kaufman DI, et al (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326:581-588
3. 3. Bowden AN, Bowden PMA, Friedmann AI, Perkin GD, Rose FC (1974) A trial of corticotrophin gelatin injection in acute optic neuritis. J Neurol Neurosurg Psychiatry 37:869-873
4. 4. Canadian Cooperative Multiple Sclerosis Study Group (1991) The Canadian cooperative trial of cyclophosphamide and plasma-exchange in progressive multiple sclerosis. Lancet 337:441-446
5. 5. Cazzato G, Mesiano T, Antonello R, Monti F, Carraro N, Torre P, et al (1995) Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis. Eur Neurol 35:193-198
6. 6. Compston A (1988) Methylprednisolone and multiple sclerosis. Arch Neurol 45:669-670
7. 7. Cook SD, Devereux C, Troiano R, Bansil S, Zito G, Sheffet A, et al (1995) Combination total lymphoid irradiation and low-dose corticosteroid therapy for progressive multiple sclerosis. Acta Neurol Scand 91:22-27
8. 8. Durelli L, Cocito D, Riccio A, Bergamasco B, Baggio GF, et al (1986) High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology 36:238-243
9. 9. Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Syndulko K, et al (1989) A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 39:1018-1026
10. 10. Gasperini C, Pozzilli C, Bastianello S, Koudriavtseva T, Colleluori A, Milleflorini E, et al (1997) The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. Acta Neurol Scand 95:201-207
11. 11. Hauser SL, Dawson DM, Lehrich JR, Flint Beal M, Kevy SV, Propper RD, et al (1983) A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma-exchange, and ACTH. N Engl J Med 308:173-180
12. 12. Hauser SL (1994) Demyelinating diseases. In: Harrison's principles of internal medicine. McGraw-Hill, New York, pp 2287-2295
13. 13. Hoogstraten MC, Minderhoud JM (1990) Long-term effects of ACTH treatment of relapse in multiple sclerosis. Acta Neurol Scand 82:74-77
14. 14. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277-1285
15. 15. Johnson KM, Brooks BR, Cohen JA, et al (1995) Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268-1276
16. 16. Kupersmith MJ, Kaufman D, Paty DW, Ebers G, McFarland H, Johnson K, et al (1994) Megadose corticosteroids in multiple sclerosis. Neurology 44:1-4
17. 17. Lhermitte F, Marteau R, de Saxcé H (1987) Traitement des formes évolutives et graves des sclérose en plaques par l'association scèrum antilymphocytaire, azathioprine, prednisone. Rev Neurol (Paris) 143:98-107
18. 18. Marforio S (1984) ACTH 1-17 effects in multiple sclerosis. La Ricerca Clin Lab 14:253-255
19. 19. Mertin J, Kremer M, Knight SC, Batchelor JR, Halliday AM, Rudge P, et al (1982) Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report. Lancet 2:351-354
20. 20. Millar JHD, Vas CJ, Noronha MJ, Liversedge LA, Rawson MD (1967) Long-term treatment of multiple sclerosis with corticotrophin. Lancet 1:429-431
21. 21. Miller H, Newell DJ, Ridley A (1961a) Multiple sclerosis: trials of maintenance treatment with prednisolone and soluble aspirin. Lancet 1:127-129
22. 22. Miller H, Newell DJ (1961b) Multiple sclerosis: treatment of acute exacerbations with corticotrophin (ACTH). Lancet 2:1120-1122
23. 23. Milligan NM, Newcombe R, Compston DAS (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. I. Clinical effects. J Neurol Neurosurg Psychiatry 50:511-516
24. 24. Perkin GD (1987) A critique of steroid trials in multiple sclerosis. Neuroepidemiology 6:209-215
25. 25. Peto R (1987) Why do we need systematic overviews of randomized trials? Stat Med 6:233-240
26. 26. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomized double-blind placebo-controlled study of interferon bbeta-1 a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
27. 27. Rawson MD, Liversedge LA, Goldfarb G (1966) Treatment of acute retrobulbar neuritis with corticotrophin. Lancet 2:1044-1046
28. 28. Rinne UK, Sonninen V, Tuovinen T (1968) Corticotrophin treatment in multiple sclerosis. Acta Neurol Scand 44:207-218
29. 29. Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA (1970) Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo. Final report. Neurology 20:1-59
30. 30. Ruutiainen J, Salonen R, Halonen P, Pamelius M, Eskola J, Salmi A (1991) Treatment of acute exacerbation in early multiple sclerosis: cyclosporin A or prednisolone? Acta Neurol Scand 83:52-54
31. 31. Seland TP, McPherson TA, Grace M, Lamoureux G, Blain JG (1974) Evaluation of antithymocyte globulin in acute relapses of multiple sclerosis. Neurology 24:34-40
32. 32. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J (1998) Double-blind, randomized, placebo, controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 51:529-534
33. 33. Tourtellotte WW, Haerer AF, Arbor A (1965) Use of an oral corticosteroid in the treatment of multiple sclerosis. Arch Neurol 12:536-545
34. 34. Tremlett HL, Luscombe DK, Wiles CM (1998) Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psychiatry 65:362-365
35. 35. Troiano R, Cook SD, Dowling PC (1987) Steroid therapy in multiple sclerosis: a point of view. Arch Neurol 44:803-807
36. 36. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, et al (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43:910-918